Adjunctive Probiotic Therapy in Major Depressive Disorder (ProMOOD)
NCT07786285 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2026-08-31
Summary
A double-blind, randomized controlled trial (RCT) aimed at evaluating the efficacy of probiotic supplementation in patients undergoing concurrent antidepressant therapy.
The study will also assess gut microbiome composition and function, and correlate microbiome changes with clinical and psychological outcomes.
Participants will be evaluated by a psychiatrist/clinician, alongside standardized psychological assessments at:
* Baseline (inclusion)
* Week 4
* Week 12
The following validated instruments will be used:
* HAM-D - Hamilton Depression Rating Scale (clinician-rated depression severity)
* BDI - Beck Depression Inventory (self-reported severity of depression)
* PSS - Perceived Stress Scale (self-reported stress perception)
Inclusion Criteria
* Age 18-65 years
* Confirmed diagnosis of depression according to ICD 11 (International Classification of Diseases) criteria
* Written informed consent
* Stable antidepressant therapy (same medication for at least 6 weeks to ensure stable clinical response)
Exclusion Criteria
* Acute suicidality
* Severe cardiovascular disease
* Pregnancy or breastfeeding
* Substance/ alcohol abuse
* Severe neurological or systemic disease
* Recent antibiotic use
* Probiotic use in past year
* Treatment resistant depression
* Psychotic depression
Sample Size
* Initial recruitment target: 150-200 participants
* Expected dropout rate: approximately 50%, based on similar studies
* Final expected sample size: \~100 participants
* Sample size calculation based on Nikolova et al., 2023.
Primary outcome Change in Hamilton Depression Rating Scale (HAM-D-17) score from baseline to Week 12.
Secondary outcomes Change in Beck Depression Inventory-II (BDI-II) score from baseline to Week 12. Change in Perceived Stress Scale (PSS-10) score from baseline to Week 12. Changes in gut microbiome composition and diversity (α-diversity, β-diversity and relative abundance of bacterial taxa) between baseline and Week 12.
Safety and tolerability of probiotic supplementation, assessed by adverse events and treatment discontinuation.
Intervention:
OmniBiotic Stress Repair
Microbiome Analysis Subgroup
Stool samples will be collected at:
* Baseline
* 1 month
* 3 months Analysis will follow methodologies similar to Mörkl S et al. (2025).
Remark: Additional sampling at 1 week (as done in the referenced study) is considered unnecessary, as it falls outside routine clinical monitoring.
Antidepressant Strategy
* Include patients receiving SSRI (Selective Serotonin Reuptake Inhibitors) and possibly SNRI (Serotonin-Norepinephrine Reuptake Inhibitors)
* Advantage: broader applicability
* Limitation: increased variability
Conditions
- Depression / Major Depressive Disorder
Interventions
- DIETARY_SUPPLEMENT
-
OMNi-BiOTiC® STRESS Repair
Participants will receive one 3-g sachet orally twice per day for 12 weeks, in addition to their existing stable antidepressant therapy. Each 3-g sachet contains at least 7.5 × 10⁹ viable bacteria from nine strains: Lactobacillus casei W56, Lactobacillus acidophilus W22, Lactobacillus paracasei W20, Bifidobacterium animalis subsp. lactis W51, Lactobacillus salivarius W24, Lactococcus lactis W19, Bifidobacterium animalis subsp. lactis W52, Lactobacillus plantarum W62, and Bifidobacterium bifidum W23. The powder will be mixed with 100-200 mL of water, allowed to activate for at least one minute, stirred again, and consumed, preferably on an empty stomach. Participants will continue the same antidepressant medication and dose throughout the intervention period unless a change is clinically required.
- OTHER
-
Matched Placebo Powder for Oral Solution
Participants will continue stable antidepressant therapy and receive a matched placebo for 12 weeks.
Sponsors & Collaborators
-
Institut AllergoSan
collaborator UNKNOWN -
University Maribor
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-10-31
- Primary Completion
- 2029-10-31
- Completion
- 2030-10-31
Countries
- Slovenia
Study Locations
More Related Trials
-
Probiotics to Treat "Inflammatory Depression"
NCT03660280 ·Status: COMPLETED ·Phase: NA
-
Lactobacillus Plantarum PS128 in Patients With Major Depressive Disorder and High Level of Inflammation
NCT03237078 ·Status: UNKNOWN ·Phase: NA
-
Effect of Consuming a Combination of Probiotic Strains on Postpartum Depression
NCT06651424 ·Status: TERMINATED ·Phase: NA
-
Effects of Probiotics on Mood
NCT03539263 ·Status: COMPLETED ·Phase: NA
-
Effect of Two Probiotic Formulations on Mental Health and Mood Biomarkers in Adults With Depressive Symptoms
NCT05564767 ·Status: COMPLETED ·Phase: NA
-
Probiotics for Depressive Symptomatology and Neural Activity.
NCT07667530 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
8-week of PS128 RCT in Patients With Major Depressive Disorder
NCT04199845 ·Status: UNKNOWN ·Phase: NA
-
A Pilot Study of Synbiotics in Adults With Depressive Symptoms
NCT06905223 ·Status: RECRUITING ·Phase: NA
-
PB-18 Probiotic for Mild to Moderate Depression
NCT07562516 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Probiotic Administration for Adolescent Depression
NCT06898788 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
The Influence of Probiotic Supplementation on Depressive Symptoms, Inflammation and Oxidative Stress Parameters and Faecal Microbiota in Patients With Depression Depending on Metabolic Syndrome Comorbidity
NCT04756544 ·Status: UNKNOWN ·Phase: PHASE3
-
The Influence of Probiotic Supplementation on the Severity of Anxiety and Depressive Symptoms, as Well as the Function and Composition of Gut Microbiota, Metabolic, Inflammation, and Oxidative Stress Markers in Patients With Depression
NCT05717946 ·Status: UNKNOWN ·Phase: PHASE2
-
Effects of a Probiotic on Aspects of Mental Wellness
NCT05905679 ·Status: COMPLETED ·Phase: NA
-
The Efficacy of Probiotic Compared With Placebo Commitment Therapy for Treatment of Major Depressive Disorder
NCT05315401 ·Status: WITHDRAWN ·Phase: PHASE2
-
Effects of Probiotics on Symptoms of Depression
NCT03277586 ·Status: TERMINATED ·Phase: PHASE3
-
Fermented Milk Product With Probiotic and Its Impact on Mood of Patients With Treatment Resistant Depression
NCT03317678 ·Status: COMPLETED ·Phase: NA
-
Effects of Probiotic Supplementation on Gut Health, Immune Response, and Well-Being
NCT07779265 ·Status: RECRUITING ·Phase: NA
-
Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder
NCT01337609 ·Status: TERMINATED ·Phase: PHASE4
-
Safety and Tolerance of a Novel Three-Strain Probiotic in Healthy Adults
NCT07566884 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Probiotic Research for Mental Health in Adult Volunteers
NCT07751614 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment
NCT02469545 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Probiotic Supplementation on State and Trait Stress, Anxiety, and Depression Symptoms in Stressed Adults
NCT07216729 ·Status: COMPLETED ·Phase: NA
-
Open-Label Clinical Trial Evaluating the Impact of a Multi-Strain Commensal Probiotic Dietary Supplement on Gastrointestinal Microbiota Composition, Functional Gastrointestinal Markers, and Gastrointestinal Symptoms
NCT07720362 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
The Effect of Probiotic Supplementation on the Mental Status, Inflammation, and Intestinal Barrier in Major Depressive Disorder Patients Using Gluten-free or Gluten-containing Diet
NCT03877393 ·Status: UNKNOWN ·Phase: NA
-
Effects of Prebiotics on Intestinal Colonization and Mood in a University Cohort
NCT05212545 ·Status: COMPLETED ·Phase: NA